News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

April 16, 2018 Apellis Pharmaceuticals Announces Proposed Offering of Common Stock
April 16, 2018 Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
March 19, 2018 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
February 23, 2018 Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
February 22, 2018 Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
January 2, 2018 Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
December 20, 2017 Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
December 19, 2017 Apellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial Officer
December 8, 2017 Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)
November 13, 2017 Apellis Pharmaceuticals Announces Closing of its Initial Public Offering